New immunosuppressives and clinical studies: an embarrassment of riches or more toxicity management? Introduction.
Guttmann
R D
RD
McGill University Faculty of Medicine and the Institute for Policy Research in Medicine and Emerging-Technologies (IPRIME), Montréal, Canada.
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000188:drug therapy; D001927:Brain Diseases / Q000188:drug therapy; D003920:Diabetes Mellitus / Q000188:drug therapy; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000145:classification / Q000627:therapeutic use*; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy; D009103:Multiple Sclerosis / Q000188:drug therapy; D018696:Neuroprotective Agents / Q000627:therapeutic use; D011565:Psoriasis / Q000188:drug therapy; D014181:Transplantation Immunology; D014183:Transplantation, Heterologous / Q000276:immunology; D014184:Transplantation, Homologous / Q000276:immunology
D007166:Immunosuppressive Agents; D018696:Neuroprotective Agents